NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

34
NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA 2 nd Ukraine Congress On Clinical Genetics October 2005

description

NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA. 2 nd Ukraine Congress On Clinical Genetics October 2005. Ukraine Elena Grechanina Russia Peter Novikov Denmark Jytte Bieber Nielsen Leah Brammer Kirstin Ahring USA Reuben Matalon, M.D., Ph.D. Kim Matalon. - PowerPoint PPT Presentation

Transcript of NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Page 1: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

NeoPhe in the Treatment of Phenylketonuria

New Formulation of LNAA

2nd Ukraine Congress

On Clinical GeneticsOctober 2005

Page 2: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

UkraineElena Grechanina

RussiaPeter Novikov

DenmarkJytte Bieber Nielsen

Leah BrammerKirstin Ahring

USAReuben Matalon, M.D., Ph.D.

Kim Matalon

Page 3: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Large Neutral Amino Acids (LNAA)

• Phenylalanine (Phe) • Leucine• Tyrosine• Tryptophan• Methionine• Histidine• Isoleucine• Valine• Threonine

Page 4: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Transport of LNAA to the Brain

• Phenylalanine (Phe) 0.12 0.45• Leucine 0.15 0.53• Tyrosine 0.16 0.58• Tryptophan 0.19 0.71• Methionine 0.19 0.77• Histidine 0.28 1.10• Isoleucine 0.33 1.30• Valine 0.63 2.50• Threonine 0.73 3.00

Km mmol/L Km app

Pardridge, Inborn Errors of Metabolism in Humans. MTP Press, 1980.

Page 5: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Andersen AE, Avins L

• LNAA injected to rat pups

• Phenylalanine hydroxylase was ihibited by parachlorophenylalanine

• Brain phenylalanine decreased

1976 Arch Neurology 33:684

Page 6: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Tyrosine in The Treatment of PKU

Lou et al used Tyr 160 mg/kg in treated patients with PKU

• Increased attention span

• Increased dopamine synthesis

1987 Acta Paediatr Scand 76:560

Page 7: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Tyrosine in Treatment of PKU

• Pietz et al. used high dose tyrosine in adults with PKU and high blood Phe

• No difference in treated group vs placebo

1995 J Pediatr 127:936

Page 8: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Tryptophan in Treated PKU

• Nielsen et al used tryptophan 4.5 gm/day to treated PKU for 3 weeks

• Showed a 3 fold increase in 5-HIAA in CSF despite high blood Phe

1988 Dietary Phenylalanine and Brain Function. Birkhauser

Page 9: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

LNAA Supplementation in PKU

• Dotremont et al. used LNAA and a low protein diet 0.6 gm/kg on 4 patients with PKU

• After 1 month subjects found with negative nitrogen balance

• Lysine was limiting amino acid

1995 J Inherit Metab Dis 18:127

Page 10: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Km (app) – Km (1 + ∑[aa]/Km]

This predicts that, if the plasma level of an LNAA is much less than its value of Km, then that amino acid will not compete effectively for the carrier protein

Page 11: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Absolute and apparent Km values of neutral amino acids for the neutral amino acid transporter in the BBB (Partridge, 1980)0

Amino acid Typical plasma level (mM)

Km

(mM)

App Km

(mM)

LNAA’s

Phe 0.05 0.12 0.45

Leu 0.10 0.15 0.53

Tyr 0.09 0.16 0.58

Trp 0.10 0.16 0.71

Met 0.04 0.19 0.77

Isoleu 0.07 0.33 1.3

Val 0.14 0.63 2.5

Thr 0.19 0.73 3.0

Page 12: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Absolute and apparent Km values of neutral amino acids for the neutral amino acid transporter in the BBB (Partridge, 1980)Amino acid

Typical plasma level (mM)

Km

(mM)

App Km

(mM)

Basic aa’s

His 0.05 0.28 1.1

Arg 0.10 0.09 0.40

Lys 0.30 0.10 0.25

Page 13: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

LNAA Transport in Intestinal Mucosa Km mmol/L

• Phenylalanine 1.0• Leucine 2.0• Valine 3.0• Methionine 5.0• Histidine 6.0• Competition effect is not likely to occur

in tissue other than brain unless high concentration of amino acids is used

Pardridge, Inborn Errors of Metabolism in Humans. MTP Press, 1980.

Page 14: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Amino acid inhibition of Phe transport in Caco-2-cells – 10uM Phe in buffer applied to monolayers in presence of 1 mM concentration of each amino acid

Inhibitor % inhibition

LNAA’s

Leu 55%

Tyr 45%

Trp 36%

Basis Aa’s

Lys 50%

His 33%Hidalgo Biochem Biophys. Acta 1008: 5-30a (1990)

Page 15: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

78- 80- 83- 86- 159- 162-

F 577 23.8 21.4 19.4 24.9 18 11

F 579 23.7 25.1 28.4 33.1 8.3 14.8

F 582 28.8 21.9 22.2 20.9 10.3 8.3

F 584 23.8 30 25.3 30.7 7.8 12.4

PKU Mice on NeoPhe phe mg/dl

Mice Control NeoPhe

Page 16: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

78- 80- 83- 86- 159- 162-

F 585 20.6 21.7 24.4 19.8 8.5 12.3

F 586 23.2 25.7 21.2 21.9 13.5 11.3

F 588 21.6 21.7 24.2 24.4 10.9 10.9

Avg each time pt 23.6 23.9 23.6 25.1 11 11.6

Avg all Pre-LNAA 24.1

Avg all Post-LNAA 11.3

PKU Mice on NeoPhe phe mg/dl

Mice Control NeoPhe

Page 17: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Pre- and Post-LNAA Blood Phe Levels

0

5

10

15

20

25

30

35

1 2 3 4 5 6

Blo

od

Ph

e [

mg

/dl]

Pre-LNAA Post-LNAA

Page 18: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Denmark LNAA STUDY1 tablet/kg/day

Blood Samples

PKU 20 PKU 39 PKU 93 PKU 105 PKU 128 Avg

1 1436 1681 1697 1597 1627 1608

02 1262 1691 1591 1480 1602 1525

04 1164 1643 1526 1414 1407 1431

1 week 184 -58 220 184 268 160

Page 19: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Denmark LNAA STUDY 2 tablets/kg/day

Blood Samples

PKU 20

PKU 39 PKU 93 PKU 105

PKU 128

Avg

08 1252 1739 1477 1413 1359 1448

09 1146 1537 1370 1233 1373 1332

11 1119 1556 1389 1179 1313 1311

15 1199 1650 1349 1222 1335 1351

2 week 237 31 348 375 292 257

Page 20: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Time Phe Tyr

KA µmol/l mg/dl µmol/l mg/dl

0’ 718.8 11.98 53.9 0.98

3 days 668.4 11.14 91.3 1.66

3 days 523.2 8.72 103.4 1.88

3 days 376.2 6.27 108.3 1.97

Russia LNAA STUDY

Page 21: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Time Phe Tyr

KN µmol/l mg/dl µmol/l mg/dl

0’ 707.4 11.79 42.9 0.78

3 days 607.2 10.12 126.5 2.30

3 days 572.4 9.54 159.5 2.91

3 days 585.6 9.76 83.6 1.52

Russia LNAA STUDY

Page 22: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Russia LNAA StudyTime Phe Tyr

KH µmol/l mg/dl µmol/l mg/dl

0’ 635.4 10.59 33.0 0.60

3 days 554.4 9.24 242.0 4.40

3 days 322.2 5.37 94.6 1.72

3 days 136.2 2.27 110.0 2.00

3 days 102.6 1.71 94.0 1.71

Page 23: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

USA LNAA STUDYTime Phe Tyr

GDL µmol/l mg/dl µmol/l mg/dl

0’ 1290.6 21.51 69.8 1.27

2 days 1198.2 19.97 73.7 1.34

4 days 115.8 1.93 140.25 2.55

KM

0’ 1540.2 25.67 30.8 0.56

8 days 883.8 14.37 53.8 0.98

0’ 1978.2 32.97 68.7 1.25

2 days 1608.6 26.81 207.35 3.77

Page 24: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

USA LNAA STUDYTime Phe Try

ES µmol/l mg/dl µmol/l mg/dl

0’ 1375.8 22.93 31.9 0.58

4-7 days 767.4 12.79 121.5 2.12

RC

0’ 965.4 16.09 58.8 1.07

2 days 828.6 13.81 156.2 2.84

Page 25: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Response of Blood Phe to LNAAUkraine

0

5

10

15

20

25

21 yo girl 21 14.5 16 7.9 12.7 7.1 13

0 24h 72hr 1 wk 2 wk 3 wk 4 wk

µmol/l 1260 870 960 474 762 426 780

Page 26: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Response on Phe on LNAAUkraine

0

5

10

15

20

25

12 yo boy 20 13.8 12.75 10.4

0 36hr 72h 1wk

µmol/l 1200 828 765 624

Page 27: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

US Blood Phe and TyrNeoPhe Patient K 1 Week

µmol/L (mg)

Control NeoPhe

phe tyr phe tyr

µmol/L (mg)

1978.1(32.97) 1.251356.0 (22.6) 5.0

1139.6 (25.66) 0.62 1308 (21.8) 4.1

1456.2 (24.27) 0.62 1146 (19.1) 3.82

24% reduction

Page 28: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

US Blood Phe and TyrNeoPhe Patient G 1 Week

µmol/L (mg)Control NeoPhe

phe tyr phe tyr

mg/dl mg/dl

1560 (26.0) 0.92 953 (15.89) 4.35

1764 (29.4) 1.9 505 (8.43) 3.32

56% reduction

Page 29: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

NeoPhe 0.5 g/kg in PKU Subjects

• 13 subjects

• Mean age 26.6 years

• 7 males, 6 females

• Mean decrease in blood Phe after one week 243 µmol/L

• Average decrease in blood Phe 22 %.

Page 30: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

NeoPhe 1.0 g/kg in PKU Subjects

• 7 subjects

• Mean age 25.2 years

• 5 males, 2 females

• Mean decrease in blood Phe after one week 377 µmol/L

• Average decrease in blood Phe 25 %.

Page 31: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Figure 1. Blood Phe Response to 0.5g/kg NeoPhe in Patients with PKU

0

200

400

600

800

1000

1200

1400

1600

1800

2000

Zero Time 1 week

Blood Phe

umol

/L

IVS12nt1g>a/R261Q

IVS12nt1g>a/Y356X

IVS12ntg>a/IVS10nt11g>a

E280K/R408W

IVS12nt1g>a/IVS12nt1g>a

R261Q/R408W

R408W/R408W

IVS4ntg>t/R408W

R408W/R408W

E280K/E280K

F299C/IVS12nt1g>a

I65T/R408W

F299C/unk

Paired t-test: p=0.001

Page 32: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Figure 2. Blood Phe Response to 1.0 g/kg NeoPhe in Patients with PKU

0

200

400

600

800

1000

1200

1400

1600

1800

Zero Time 1 week

Blood Phe

umol

/L

IVS12nt1g>a/R261Q

IVS12nt1g>a/Y356X

IVS12nt1g>a/IVS10nt11g>a

E280K/R408W

IVS12nt1g>a/IVS12nt1g>a

ND

R408W/R252W

Paired t-test: p=0.006

Page 33: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

CONCLUSIONS

• For the first time mixture of LNAA can lower blood phenylalanine

• Using NeoPhe avoids lysine deficiency and negative nitrogen balance

• NeoPhe offers new options to treat PKU

• Diet can be more liberal with NeoPhe

• Still blood phe levels need to be controlled

Page 34: NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

Acknowledgement

Participants in the study

Professor Elena GrechaninaKharkiv, Ukraine

Professor Peter NovikovMoscow, Russia

Dr. Jytte Bieber NielsenGlostrup, Denmark